Pantherna Therapeutics presented at the RNA Therapeutics Conference in London, UK.
Dr. Klaus Giese provided an outline of Pantherna’s therapeutic programs [...]
Pantherna Therapeutics to present at BIO-Europe 2019
Dr. Klaus Giese (CEO) will present in the Start-Up Slam [...]
Pantherna Therapeutics to present at mRNA Health Conference 2019
Dr. Daniel Tondera and Dr. Jörg Kaufmann (CSO) will attend [...]
Pantherna Therapeutics to present at the Creative Transformative Medicine Europe User Group Meeting
Dr. Oliver Keil (CTO), Dr. Volker Fehring (Head of Formulation) [...]
“First-in-Class“ mRNA-therapeutics for vascular diseases: Pantherna Therapeutics receives 7-digit investment
The life science start-up Pantherna Therapeutics secures €3.5 million [...]
Pantherna Therapeutics participated as a finalist at BioRiver Boost! 2018 in Wuppertal.
The Company was presented by Dr. Klaus Giese, Chief Executive [...]
Pantherna Therapeutics filed its first patent application “Recombinant nucleic acid construct”.
The patent filing of our ideas with confirming experimental data [...]
Pantherna Therapeutics presented at Biovaria in Munich.
Dr. Klaus Giese, Pantherna’s CEO, provided an overview of the [...]
Pantherna Therapeutics contracted with the Institute of Biomaterial Research of the Helmholtz-Zentrum Geesthacht.
Under this contract the Institute will generate and functionally evaluate [...]
Pantherna Therapeutics attended the BIO.NRW Business Angel ZIRKEL in Duesseldorf.
Dr. Gerrit Maaß, Chief Financial Officer, and Dr. Klaus Giese, [...]